Fig. 5From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysisForest plots of WMD of PPPM associated with pazopanib versus sunitinibBack to article page